Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Bacharach

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Ophthalmology (Auckland, N.Z.)|November 6, 2025
Expert Opinion to Optimize Clinical Outcomes of Bimatoprost Intracameral Implant TreatmentCourtney Bovee, Jason Bacharach, Inder Paul Singh, et al.
American Journal of Ophthalmology|February 23, 2024
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)Jason Bacharach, Jacob W Brubaker, David G Evans, et al.
Investigative Ophthalmology & Visual Science|June 9, 2016
Impact of Dry Eye Disease on Work Productivity, and Patients' Satisfaction With Over-the-Counter Dry Eye TreatmentsKelly K Nichols, Jason Bacharach, Edward Holland, et al.
Ophthalmology and Therapy|July 10, 2024
Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular HypertensionJason Bacharach, Long V Doan, Kerry G Stephens, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Journal of Glaucoma|September 15, 2025
Safety and Efficacy of a Preservative-Free Bimatoprost 0.01% Ophthalmic Gel: Results From a Phase III Controlled TrialEydie Miller-Ellis, James H Peace, Douglas G Day, et al.
Journal of Glaucoma|September 9, 2005
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionBret A Hughes, Jason Bacharach, E Randy Craven, et al.
Ophthalmology|November 8, 2018
24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized TrialRobert N Weinreb, Jason Bacharach, Robert D Fechtner, et al.
Journal of Glaucoma|May 12, 2023
Negative Pressure Application via a Multi-Pressure Dial to Lower IOP in Patients with Suspected Glaucoma or Open Angle GlaucomaThomas W Samuelson, Tanner J Ferguson, Jacob W Brubaker, et al.
American Journal of Ophthalmology|March 14, 2019
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 StudyAlbert S Khouri, Janet B Serle, Jason Bacharach, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Ophthalmology (Auckland, N.Z.)|November 6, 2025
Expert Opinion to Optimize Clinical Outcomes of Bimatoprost Intracameral Implant TreatmentCourtney Bovee, Jason Bacharach, Inder Paul Singh, et al.
American Journal of Ophthalmology|February 23, 2024
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)Jason Bacharach, Jacob W Brubaker, David G Evans, et al.
Investigative Ophthalmology & Visual Science|June 9, 2016
Impact of Dry Eye Disease on Work Productivity, and Patients' Satisfaction With Over-the-Counter Dry Eye TreatmentsKelly K Nichols, Jason Bacharach, Edward Holland, et al.
Ophthalmology and Therapy|July 10, 2024
Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular HypertensionJason Bacharach, Long V Doan, Kerry G Stephens, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 17, 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye diseaseJoseph Tauber, Barry A Schechter, Jason Bacharach, et al.
Journal of Glaucoma|September 15, 2025
Safety and Efficacy of a Preservative-Free Bimatoprost 0.01% Ophthalmic Gel: Results From a Phase III Controlled TrialEydie Miller-Ellis, James H Peace, Douglas G Day, et al.
Journal of Glaucoma|September 9, 2005
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionBret A Hughes, Jason Bacharach, E Randy Craven, et al.
Ophthalmology|November 8, 2018
24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized TrialRobert N Weinreb, Jason Bacharach, Robert D Fechtner, et al.
Journal of Glaucoma|May 12, 2023
Negative Pressure Application via a Multi-Pressure Dial to Lower IOP in Patients with Suspected Glaucoma or Open Angle GlaucomaThomas W Samuelson, Tanner J Ferguson, Jacob W Brubaker, et al.
American Journal of Ophthalmology|March 14, 2019
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 StudyAlbert S Khouri, Janet B Serle, Jason Bacharach, et al.
Pageof 5